TH1701004531A - VariantRNAi - Google Patents
VariantRNAiInfo
- Publication number
- TH1701004531A TH1701004531A TH1701004531A TH1701004531A TH1701004531A TH 1701004531 A TH1701004531 A TH 1701004531A TH 1701004531 A TH1701004531 A TH 1701004531A TH 1701004531 A TH1701004531 A TH 1701004531A TH 1701004531 A TH1701004531 A TH 1701004531A
- Authority
- TH
- Thailand
- Prior art keywords
- rnai
- sequence
- ricombinant
- disease
- conducting
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 abstract 4
- 230000009368 gene silencing by RNA Effects 0.000 abstract 4
- 239000004020 conductor Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 241000713666 Lentivirus Species 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Abstract
บทสรุปการประดิษฐ์ซึ่งจะปรากฏบนหน้าประกาศโฆษณาReadFile:หน้า1ของจำนวน1หน้าบทสรุปการประดิษฐ์ที่ถูกจัดให้มีในที่นี้คือโมเลกุลRNAiที่รวมถึงสายที่หนึ่งที่มีลำดับตัวนำและสายที่สองที่ประกอบรวมด้วยลำดับที่ไม่ใช่ตัวนำเมื่อลำดับที่ไม่ใช่ตัวนำมีส่วนนู้นตรงข้ามบริเวณสีดของลำดับตัวนำ;เช่น,ตรงข้ามลำดับการตัดในบางลักษณะ,การประดิษฐ์นี้จัดให้มีRNAiสำหรับการบำบัดโรคฮันติงตันที่ยังถูกจัดให้มีในที่นี้คือแถบการแสดงออก,เวกเตอร์(เช่น,rAAV,เวกเตอร์อะดีโนไวรัสแบบริคอมบิแนนท์,เลนติไวรัสแบบริคอมบิแนนท์,และHSVแบบริคอมบิแนนท์),เซลล์,อนุภาคไวรัส,และองค์ประกอบทางเภสัชกรรมที่มีRNAiที่ยังคงถูกจัดให้มีในที่นี้คือวิธีการและชุดคิตเกี่ยวข้องกับการใช้RNAi,ตัวอย่างเช่น,เพื่อบำบัดโรคฮันติงตัน The Invention Summary, which appears on the ReadFile:1 page of the Invention Summary page, is provided herein for the RNAi molecule, which includes the first strand containing the conductor sequence and the second strand that composes. Incorporated with non-conducting sequences when the non-conducting sequence has an opposite part of the black region of the conductor sequence; for example, opposite the cut-off sequence in some manner, this invention provides RNAi for the therapy of Huntington's disease. Also provided here are expression bands, vectors (eg, rAAV, ricombinant adenovirus vector, ricombinant lentivirus, and ricom HSV). binant), cells, viral particles, and pharmaceutical constituents containing RNAi that are still provided herein are methods and kits related to the use of RNAi, for example, to treat Hunting's disease. ton
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH1701004531A true TH1701004531A (en) | 2022-05-23 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791805A1 (en) | OPTION MEANS FOR RNAi | |
| PH12019500068A1 (en) | Novel adeno-associated virus capsid proteins | |
| PH12020500466A1 (en) | Lipid nanoparticle formulations of non-viral, capsid-free dna vectors | |
| CY1119563T1 (en) | OPTIMIZATION OF ANTIBODIES Binding to Lymphocyte Activation Gene-3 (LAG-3), AND USES THEREOF | |
| MX2018010824A (en) | Inducible binding proteins and methods of use. | |
| MX2019010972A (en) | High affinity mage-a1-specific tcrs and uses thereof. | |
| BR112018011711A2 (en) | targeting peptides to target adeno-associated virus (aav) | |
| JOP20190248A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| GEP20227447B (en) | Constructs having sirp-alpha domain or variant thereof | |
| EA201792573A1 (en) | TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION | |
| WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
| EA201691111A1 (en) | CHEMERAL PROTEINS OF FACTOR VIII AND THEIR APPLICATION | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| WO2018191750A3 (en) | Novel delivery of large payloads | |
| MX2018009011A (en) | Anti-ror1 antibodies and uses thereof. | |
| AR108683A1 (en) | RECOMBINANT AAV VECTORS THAT EXPRESS OSTEOPROTECTOR GENES THAT INCLUDE HAS2 AND LUBRICIN, OF USEFULNESS IN THE TREATMENT OF OSTEOARTHRITIS AND ARTICULAR AFFECTIONS RELATED IN MAMMALS | |
| PH12020550117A1 (en) | Variant rnai | |
| MX2020002921A (en) | Claudin6 antibodies and methods of treating cancer. | |
| SA519401756B1 (en) | Frataxin Expression Constructs | |
| WO2014151982A3 (en) | Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment | |
| EA201691120A1 (en) | VECTOR COMPOSITIONS AND METHODS OF INDUCTION OF STRENGTHENED IMMUNE RESPONSE USING POXVIRUS VECTORS | |
| CR20200642A (en) | Immunodominant proteins and fragments in multiple sclerosis | |
| MX2020001287A (en) | Braf-specific tcrs and uses thereof. | |
| WO2014111840A3 (en) | Peptide | |
| TH1701004531A (en) | VariantRNAi |